Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment

Nature Medicine(2024)10.1038/s41591-024-03040-4Source: DataRank Database

Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment is a research paper published in Nature Medicine (2024). On theSindex it has a DataRank of 2.1. It has been cited 107 times, with 94 citing works in its 1-hop citation network.

N/A

2.1DataRank · unranked

Scored on demand from live citation data

Open Access107 citations · 94 citing works in its network

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (18 grants)Impact (FWCI 19.86)OA: goldTopics (51)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 33%Citation Network 67%

Base Score Contribution

0.702

From this paper's citation signal

Citation Network Contribution

1.4

From 62 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 94 citers.

Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial
The Lancet Oncology202527 citations27 referencesContributes 0.123
Whole genome sequencing-powered ctDNA sequencing for breast cancer detection
Annals of Oncology202546 citations32 referencesContributes 0.120
Circulating tumour DNA in patients with stage III colon cancer: multicentre prospective PROVENC3 study
British journal of surgery20256 citations27 referencesContributes 0.072
Circulating tumor DNA as a biomarker for progression and survival in esophageal cancer after neoadjuvant therapy and esophagectomy: a systematic review and meta-analysis
International Journal of Surgery20258 citations32 referencesContributes 0.069
Low-coverage whole genome sequencing of cell-free DNA to predict and track immunotherapy response in advanced non-small cell lung cancer
Journal of Experimental & Clinical Cancer Research202513 citations41 referencesContributes 0.064

Authors (61)

Minita Shah,Amanda Frydendahl ORCID,Daniel Halmos ORCID,Cole C. Khamnei ORCID,Nadia Øgaard ORCID

Live enrichment

PubMed:38877116 PMC:PMC7616143 OpenAlex:https://openalex.org/W4399679571

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Grant: CA263301-01A1

Melanoma Research Alliance

Grant: 1039927

Medical Research Council

Grant: CC2044

NCI NIH HHS

Grant: K08 CA263301

Novo Nordisk Fonden

Grant: NNF17OC0025052

NCI NIH HHS

Grant: R01 CA266619

Novo Nordisk Fonden

Grant: NNF22OC0074415

NCI NIH HHS

Grant: P30 CA008748

NCI NIH HHS

Grant: T32 CA079443

Cancer Research UK

Grant: 29911

NCI NIH HHS

Grant: U01 CA247439

Wellcome Trust

Grant: unidentified

unidentified

National Institutes of Health

Grant: 5K08CA263301-02

Advanced machine learning to empower ultra-sensitive liquid biopsy in melanoma and non-small cell lung cancer

National Institutes of Health

Grant: 1R01CA266619-01

Genome-wide mutational integration for ultra-sensitive plasma tumor burden monitoring in immunotherapy

National Institutes of Health

Grant: 2P30CA008748-43

MOUSE GENETICS

National Institutes of Health

Grant: 5U01CA247439-02

Deciphering Clonal Evolution in Hereditary Renal Cell Carcinomas

Wellcome Trust

FWCI

19.86

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

goldLicense: other-oa

https://pure.au.dk/portal/en/publications/5c97286d-b624-40be-b7ac-5d9a73def821

publisherhttps://www.nature.com/articles/s41591-024-03040-4.pdf

publisherhttps://www.nature.com/articles/s41591-024-03040-4

journalhttps://doi.org/10.1038/s41591-024-03040-4

Fields of Study

Cancer Genomics and DiagnosticsAI in cancer detectionRadiomics and Machine Learning in Medical Imaging03 medical and health sciences0302 clinical medicineHumansCirculating Tumor DNADNA Copy Number VariationsMachine LearningNeoplasm, ResidualTumor BurdenWhole Genome SequencingNeoplasmsPolymorphism, Single NucleotideBiomarkers, TumorColorectal NeoplasmsLung Neoplasms

MeSH Terms

Machine LearningWhole Genome SequencingCirculating Tumor DNAHumansLung NeoplasmsNeoplasmsBiomarkers, TumorColorectal NeoplasmsNeoplasm, ResidualPolymorphism, Single NucleotideTumor BurdenDNA Copy Number Variations

Keywords

SIGNAL (programming language)Computer scienceMedicineComputational biologyBiologyNeoplasm, ResidualLung NeoplasmsDNA Copy Number VariationsWhole Genome SequencingGenome Integrity & RepairTumour BiologyPolymorphism, Single NucleotideCirculating Tumor DNATumor BurdenMachine LearningSignalling & OncogenesNeoplasmsBiomarkers, TumorHumansColorectal NeoplasmsGenetics & GenomicsComputational & Systems Biology

Sustainable Development Goals

SDG 3: 3. Good health